{"url_path":"/sec/capr/8-k/2026-06-26/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 ****Financial Statements and Exhibits.  **","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-26","source_url":"https://www.sec.gov/Archives/edgar/data/1133869/0001104659-26-078327-index.html","accession_number":"0001104659-26-078327","cik":"0001133869","ticker":"CAPR","issuer_name":"CAPRICOR THERAPEUTICS, INC.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1133869/0001104659-26-078327-index.html","primary_entity_key":"0001133869","primary_entity_name":"CAPRICOR THERAPEUTICS, INC."},"word_count":110,"has_tables":true,"body_markdown":"**Item 9.01****Financial Statements and Exhibits.  **\n\n​\n\n**(d) Exhibits**\n\n​\n\n99.1\n\n​\n\n[Press Release, titled “Capricor Therapeutics Announces FDA Advisory Committee Meeting to Review BLA for Deramiocel for the Treatment of Duchenne Muscular Dystrophy”, dated June 26, 2026.](capr-20260626xex99d1.htm)\n\n​\n\n​\n\n​\n\n104\n\n​\n\nCover Page Interactive Data File (formatted as inline XBRL).\n\n​\n\n2\n\n​\n\n**SIGNATURES**\n\n​\n\nPursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.\n\n​\n\n**CAPRICOR THERAPEUTICS, INC.**\n\nDate: June 26, 2026\n\nBy:\n\n/s/ Linda Marbán, Ph.D.\n\nLinda Marbán, Ph.D.\n\nChief Executive Officer\n\n​\n\n​\n\n3"}